Cover Image

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study

Objective: Our study aims to assess the effectiveness and safety profile of Disitamab Vedotin (DV, RC48-ADC), an innovative humanized anti-HER2 antibody conjugated with tubulin-disrupting antimitotic drug monomethyl auristatin E (MMAE) via a cleavable peptide linker. This treatment combined immune c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yongbao Wei (Author), Ruochen Zhang (Author), Chenbo Yu (Author), Zhiwei Hong (Author), Le Lin (Author), Tao Li (Author), Jianhui Chen (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Investigation of awareness rate of prostate-specific antigen (PSA) among the general public in China and analysis of influencing factors
by: Yuqin Wang, et al.
Published: (2023)

Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy
by: Fan Shi, et al.
Published: (2022)

UBC Mediated by SEPT6 Inhibited the Progression of Prostate Cancer
by: Ruochen Zhang, et al.
Published: (2021)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
by: Yongbao Wei, et al.
Published: (2023)

Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients
by: Kejia Zhu, et al.
Published: (2024)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
by: Moussa M, et al.
Published: (2021)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
by: Christof Vulsteke, et al.
Published: (2023)

Dioscin Promotes Prostate Cancer Cell Apoptosis and Inhibits Cell Invasion by Increasing SHP1 Phosphorylation and Suppressing the Subsequent MAPK Signaling Pathway
by: Shuyun He, et al.
Published: (2020)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
by: Agnieszka Giza, et al.
Published: (2023)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
by: Christina D. Enescu, BS, et al.
Published: (2022)

Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract
by: Kok Hoe Chan MD, et al.
Published: (2024)

Human epidermal growth factor receptor 2 status in urothelial bladder carcinoma: Frequency, genomic patterns and clinical significance
by: Tianxi Yu, et al.
Published: (2023)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024)

Plasmacytoid urothelial carcinoma of the bladder
by: Meihua Qin, et al.
Published: (2014)

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors
by: Leonid Gibiansky, et al.
Published: (2022)

Local delivery of checkpoints antibodies
by: Chao Wang, et al.
Published: (2017)

Urothelial Calcium-Sensing Receptor Modulates Micturition Function via Mediating Detrusor Activity and Ameliorates Bladder Hyperactivity in Rats
by: Wei-Yi Wu, et al.
Published: (2021)

Bibliometric analysis of immunotherapy for bladder cancer: A correspondence
by: Ruochen Bao, et al.
Published: (2024)

Opium and grade of urothelial bladder cancer
by: Shahryar Zeighami, et al.
Published: (2018)

Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma
by: Yuxuan Song, et al.
Published: (2024)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
by: Di Wang, et al.
Published: (2021)

Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors
by: Chaitali Passey, et al.
Published: (2023)

Cost of illness of urothelial bladder cancer in Italy
by: Gerace C, et al.
Published: (2017)

CD10 expression in urothelial carcinoma of the bladder
by: Bozkurt Erol R, et al.
Published: (2009)

Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
by: Chia-Hsien Shih, et al.
Published: (2024)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
by: Lilong Zhang, et al.
Published: (2022)

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
by: Dan Liu, et al.
Published: (2024)

Expression significance of Emi1, UBCH10 and CyclinB1 in esophageal squamous cell carcinoma
by: Hui Li, et al.
Published: (2023)

Single cutaneous metastasis due to bladder urothelial carcinoma
by: Onexy Veranes Velázquez, et al.
Published: (2016)

Immunohistochemical markers in predicting behavior of bladder urothelial carcinoma
by: Simin Torabinezhad, et al.
Published: (2024)

Carcinomas in the bladder with papillary and pseudopapillary morphology - not always urothelial
by: Daniel Abensur Athanazio, et al.
Published: (2020)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
by: Gopalakrishnan D, et al.
Published: (2018)

Pathologic collision of urinary bladder urothelial carcinoma with small cell carcinoma: a case report
by: Wei Jiang, et al.
Published: (2023)

Localized amyloidosis of the urinary bladder, clinically masquerading as bladder cancer
by: DeSouza Maria, et al.
Published: (2008)

Mechanisms of Glucocorticoid Resistance in Idiopathic Nephrotic Syndrome
by: Ruochen Che, et al.
Published: (2013)

PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma
by: Liu M, et al.
Published: (2021)

Clinical significance and expression of SLC35F6 in bladder urothelial carcinoma
by: Jinling Zhang, et al.
Published: (2024)

Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder
by: Teh Bin T, et al.
Published: (2010)

Urothelial Papilloma of the Urinary Bladder in Children: Report of Two Cases
by: Kata Davidovics, et al.
Published: (2020)

Invasive bladder urothelial carcinoma, plasmacytoid variant: case report
by: Rui Pedro C. M. Oliveira, et al.